Bruns Ingmar
Chief Medical Officer
Bruns Ingmar has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Feb 10, 2026.
On the most recent filing, Bruns Ingmar is listed as Chief Medical Officer at Zentalis Pharmaceuticals, Inc. Inside the rolling window, Bruns Ingmar reported no open-market purchases and 2 open-market sales totaling $8K in ZNTL. The largest disclosed transaction in the window is a sale of 2,962 ZNTL shares on Feb 6, 2026, worth $7K.
Companies traded
Other insiders at ZNTL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$8K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Bruns Ingmar made?
Bruns Ingmar has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.
Which companies does Bruns Ingmar trade?
Bruns Ingmar has filed SEC Form 4 disclosures for 1 company, including ZNTL.
When was Bruns Ingmar's most recent SEC Form 4 filing?
Bruns Ingmar's most recent SEC Form 4 filing on Tracefour is dated Feb 10, 2026.
What is Bruns Ingmar's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Bruns Ingmar is listed as Chief Medical Officer.
What is Bruns Ingmar's total buy and sell value in the current window?
Inside the rolling retention window, Bruns Ingmar bought $0 and sold $8K based on SEC Form 4 filings.
What was Bruns Ingmar's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,962 ZNTL shares on 2026-02-06, worth $7K, per SEC Form 4 filings.